Published Technical Disclosure Archive

Human Cytomegalovirus GB Polypeptide-Based Solutions for Environmental and Industrial Applications

Publication ID: 24-11857622_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Human Cytomegalovirus GB Polypeptide-Based Solutions for Environmental and Industrial Applications,” Published Technical Disclosure No. 24-11857622_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857622_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,622.

Summary of the Inventive Concept

This inventive concept leverages the core technology of engineered human cytomegalovirus GB polypeptides to develop novel solutions for wastewater treatment, heavy metal detection, air quality monitoring, biofuel generation, and foodborne pathogen detection.

Background and Problem Solved

The original patent disclosed engineered human cytomegalovirus GB polypeptides with improved stability and immunogenicity for vaccine applications. However, the limitations of the original patent are its focus on vaccine development, neglecting the potential of these polypeptides in other industries. This inventive concept addresses the need for innovative solutions in environmental and industrial fields, where the unique properties of these polypeptides can be exploited.

Detailed Description of the Inventive Concept

The newly generated claims describe a system for treating wastewater, a method for detecting heavy metals, a device for monitoring air quality, a process for generating biofuels, and a biosensor for detecting foodborne pathogens, all utilizing engineered human cytomegalovirus GB polypeptides. These polypeptides are engineered to possess at least two amino acid mutations, including at least one engineered disulfide mutation, which enables their application in these diverse fields. The mutations confer specific binding properties, allowing the polypeptides to interact with pollutants, heavy metal ions, biomass, and pathogens.

Novelty and Inventive Step

The novelty of this inventive concept lies in the application of engineered human cytomegalovirus GB polypeptides in entirely new industries, leveraging their unique properties to solve pressing environmental and industrial problems. The inventive step is the recognition of the potential of these polypeptides beyond vaccine development and the design of novel solutions that capitalize on their capabilities.

Alternative Embodiments and Variations

Alternative embodiments of this inventive concept could include the use of different engineered disulfide mutations, varying the number and type of amino acid mutations, or exploring other industries where the polypeptides' properties could be valuable. Variations could also involve combining the polypeptides with other technologies or materials to enhance their performance.

Potential Commercial Applications and Market

The commercial potential of this inventive concept is substantial, with applications in wastewater treatment, environmental monitoring, biofuel production, and food safety. The target industries include environmental remediation, industrial manufacturing, and healthcare, offering a broad market for these innovative solutions.

CPC Classifications

SectionClassGroup
A A61 A61K39/245
C C07 C07K14/045
C C12 C12N7/00
C C12 C12N2710/16134

Field of Art

Molecular virology, protein engineering, and biotechnology, with expertise in cytomegalovirus glycoprotein modification and applications in biomolecular engineering

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology or biochemistry, experienced in protein engineering techniques, familiar with viral protein structure-function relationships, and capable of applying protein modifications across different technological domains

Obviousness Rationale

A person of ordinary skill would recognize that the engineered CMV glycoprotein B mutations disclosed in the source patent inherently suggest broader applications beyond their original context. The specific disulfide mutations and structural modifications provide a versatile molecular platform that could be predictably adapted to various sensing and environmental technologies. The PTD's applications represent a natural extension of the source patent's core technological insights about protein engineering and stability modifications.

Obvious Combinations & Variations

Source Patent Element
Engineered CMV glycoprotein B with at least two amino acid mutations including disulfide mutations
PTD Variation
Applying the mutated protein as a wastewater treatment agent for pollutant removal
Obviousness Reasoning
A PHOSITA would recognize that protein engineering techniques enabling specific binding and structural stability could be readily adapted to environmental remediation applications using predictable molecular interaction principles
Source Patent Element
Prefusion-specific protein stability modifications
PTD Variation
Utilizing mutated glycoprotein for heavy metal detection and biosensing
Obviousness Reasoning
The source patent's focus on protein stability and binding characteristics directly suggests potential sensing applications, representing a known technique of repurposing engineered proteins for detection technologies
Source Patent Element
Trimer configuration of engineered glycoprotein
PTD Variation
Developing air quality monitoring devices incorporating the protein structure
Obviousness Reasoning
The structural insights from the source patent provide a clear technological foundation for creating sensor platforms, representing a predictable application of protein engineering principles
Source Patent Element
Specific amino acid mutations enabling protein modifications
PTD Variation
Biofuel generation process using engineered glycoprotein as a conversion catalyst
Obviousness Reasoning
A PHOSITA would recognize that protein engineering techniques enabling specific molecular interactions could be systematically explored for biomass conversion applications
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857622, the variations disclosed herein represent obvious extensions of known protein engineering techniques, wherein a person having ordinary skill in the art would readily recognize the potential for adapting engineered cytomegalovirus glycoprotein B mutations across diverse technological domains through routine experimentation and well-understood molecular modification strategies.

Original Patent Information

Patent NumberUS 11,857,622
TitleHuman cytomegalovirus GB polypeptide
Assignee(s)Pfizer Inc.